Obesity And Resulting MAFLD Now the Leading Cause of Liver Transplant

Summary: Obesity and metabolic-associated fatty liver disease (MAFLD) have become the leading causes of liver transplants, surpassing viral hepatitis and alcoholic liver disease. The rise of MAFLD, driven by metabolic dysfunction, highlights the need for early diagnosis and intervention to prevent liver failure. Awareness and early treatment can help reverse this condition, reducing the need for liver transplants.

 When people think of obesity, they associate it with an increased risk of diabetes, heart disease, and stroke. However, there is much more to it. Obesity or metabolic disorders are among the leading causes of many other diseases. Thus, obesity is also the leading cause of liver failure, and hence liver transplant.

It is vital to start understanding that obesity is a risk factor for a range of health issues and not just an increased risk of heart disease and diabetes.

A liver transplant is needed when most of the functional liver cells have died, causing liver cirrhosis. In liver cirrhosis, these functional cells are replaced by the connective tissue. This formation of connective tissues is a slow process that occurs slowly over the years, resulting in liver fibrosis, which finally progresses to cirrhosis. Once most of the working liver cells have been destroyed, a liver transplant remains the only option.

Schedule An Appointment With Us Today

Liver fibrosis is the result of chronic liver injury, where excessive connective tissue builds up in the liver. This condition arises from the liver's attempt to repair itself after continuous damage, such as from alcohol abuse, viral hepatitis, or metabolic disorders. Over time, untreated liver fibrosis can progress to cirrhosis, a more severe condition characterized by the replacement of normal liver tissue with scar tissue. Cirrhosis not only impairs the liver's ability to function but also increases the risk of liver failure and hepatocellular carcinoma (liver cancer).

Metabolic-associated fatty liver disease (MAFLD) is a recently coined term that reflects the metabolic origins of fatty liver disease, distinguishing it from alcohol-related liver damage. Previously referred to as non-alcoholic fatty liver disease (NAFLD), MAFLD is linked to metabolic syndrome, which includes conditions such as obesity, type 2 diabetes, hypertension, and dyslipidemia. Unlike alcoholic fatty liver disease, MAFLD is driven by metabolic dysfunction rather than alcohol consumption.

MAFLD represents a spectrum of liver conditions, ranging from simple steatosis (fat accumulation in the liver) to non-alcoholic steatohepatitis (NASH), which includes inflammation and liver cell damage in addition to fat accumulation. 

If left untreated, NASH can progress to liver fibrosis and, ultimately, cirrhosis. The rising prevalence of obesity and type 2 diabetes globally has made MAFLD the leading cause of liver disease, surpassing even hepatitis and alcohol-related liver damage.

Understanding MAFLD is crucial for the early identification and management of patients at risk of developing advanced liver disease. Given the increasing rates of metabolic disorders worldwide, addressing the underlying metabolic dysfunction is key to preventing the progression of liver fibrosis and cirrhosis in patients with MAFLD. 

It is also vital to realize how the landscape of liver transplants has changed over the years. Just a couple of decades back, viral hepatitis was the leading cause of liver fibrosis and resulting cirrhosis. Hence, it was the leading cause of liver transplants. However, with the introduction of antiviral agents, things have improved. 

Now, the leading causes of liver transplant are alcoholic liver disease (ALD) and MAFLD. It is vital to realize that both are highly preventable conditions. Not only that, things are changing fast, and MAFLD is already a leading cause of liver transplants in females. Researchers think that it is just a matter of time before MAFLD will also become a leading cause of liver transplant in males, and thus the number one overall cause of liver transplant in the US.

But that is not all. When it comes to MAFLD, outcomes of liver transplants are not good due to the coexistence of too many other health issues. Those living with MAFLD are quite likely to have cardiovascular diseases, chronic kidney disease, and many other health issues. This means that long-term outcomes for such patients are not encouraging.

To prevent this issue, it is vital to raise awareness. People need to understand that obesity, metabolic disorders, and resulting MAFLD are now the leading causes of liver failure and, thus, liver transplant needs. 

Fortunately, the condition is not only highly preventable but also reversible if diagnosed early. To prevent the condition, it is vital to treat liver fibrosis. Liver fibrosis can be readily diagnosed using commonly available liver tests and FIB scores. FIB Score is a highly reliable way of understanding the risk of liver fibrosis and liver failure.